|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for IL11 |
 Gene summary |
| Basic gene Info. | Gene symbol | IL11 |
| Gene name | interleukin 11 | |
| Synonyms | AGIF|IL-11 | |
| Cytomap | UCSC genome browser: 19q13.3-q13.4 | |
| Type of gene | protein-coding | |
| RefGenes | NM_000641.3, NM_001267718.1, | |
| Description | adipogenesis inhibitory factorinterleukin-11oprelvekin | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 147681 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000095752 | ||
| HPRD : 00980 | ||
| Vega : OTTHUMG00000180789 | ||
| Protein | UniProt: P20809 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_IL11 | |
| BioGPS: 3589 | ||
| Pathway | NCI Pathway Interaction Database: IL11 | |
| KEGG: IL11 | ||
| REACTOME: IL11 | ||
| Pathway Commons: IL11 | ||
| Context | iHOP: IL11 | |
| ligand binding site mutation search in PubMed: IL11 | ||
| UCL Cancer Institute: IL11 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0008284 | positive regulation of cell proliferation | 2145578 | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 7508917 | GO:0043410 | positive regulation of MAPK cascade | 7508917 | GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 7508917 | GO:0046888 | negative regulation of hormone secretion | 7867561 | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 7508917 |
| Top |
| Ligand binding site mutations for IL11 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D67 | G68R | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for IL11 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | D67 | G68R | -0.41407757 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for IL11 from PDB |
| Top |
| Differential gene expression and gene-gene network for IL11 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for IL11 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0000786 | Abortion, Spontaneous | 1 | Biomarker |
| umls:C0010692 | Cystitis | 1 | Therapeutic |
| umls:C0860207 | Drug-Induced Liver Injury | 1 | Therapeutic |
| umls:C0013604 | Edema | 1 | Therapeutic |
| umls:C0019080 | Hemorrhage | 1 | Therapeutic |
| umls:C0023895 | Liver Diseases | 1 | Therapeutic |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for IL11 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of IL11 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | ARF | FORMAMIDE | 4mhl | A | D67 |
| Top |
| Conservation information for LBS of IL11 |
| Multiple alignments for P20809 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |